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Coralline hydroxyapatite/calcium carbonate (CHACC) is a biodegradable and osteoconductive bone graft material with promising
clinical performance. CHACC has been shown to support proliferation and osteogenic diﬀerentiation of human bone marrow
mesenchymal stem cells (MSCs) in vitro and demonstrated to work as a functional scaﬀold for bone formation in vivo.
Umbilical cord matrix is a more accessible and abundant tissue source of MSCs, but its osteogenic capacity in comparison to
human bone marrow when cultured on CHACC has not yet been demonstrated. In this study, we assessed the osteogenic
diﬀerentiation capacity of human MSCs, isolated from bone marrow and umbilical cord matrix and characterised by ﬂow
cytometry, when cultured on 200–300 μm CHACC granules. The 3D cultures were characterised by brightﬁeld and scanning
electron microscopy (SEM). Osteogenic potential was assessed by immunocytochemistry and qPCR for key markers of bone
diﬀerentiation (alkaline phosphatase, runx2, type I collagen, and osteocalcin). By day 1, the MSCs had enveloped the surface of
the CHACC granules to form organoids, and by day 7, cells had proliferated to bridge nearby organoids. Extracellular matrix
deposition and osteogenic diﬀerentiation were demonstrated by MSCs from both tissue sources at day 21. However, MSCs from
bone marrow demonstrated superior osteogenic diﬀerentiation capability compared to those from umbilical cord matrix. In
conclusion, it is possible to culture and induce osteogenic diﬀerentiation of umbilical cord matrix MSCs on CHACC. Further
research is required to optimise the osteogenicity of umbilical cord matrix MSCs to release their full potential as a readily
available, accessible, and abundant tissue source for bone tissue engineering.
1. Introduction
Of the diverse range of scaﬀolds available for use in maxillo-
facial surgery and dentistry, autografts have been reported to
be the “gold standard” with respect to bone grafting proce-
dures [1]. However, harvesting of autografts, usually from
the iliac crest, requires surgical intervention, which is asso-
ciated with additional risks of blood loss, infection, and
morbidity, and supply is limited [2, 3]. Other types of grafts
include allografts and xenografts, but these can cause an
immunological reaction and be rejected by the recipient [3];
so, it is vital to identify suitable alternative materials.
Synthetic biomaterials, such as hydroxyapatite, trical-
cium phosphate ceramics and cements, and bioglass, are
alternative sources for bone graft substitutes. However, these
synthetic biomaterials do not mimic the architecture, poros-
ity, and organic components of the natural bone and are not
optimal in regard to biodegradation and host tissue integra-
tion or practical to implant or inject. Naturally occurring
coral exoskeleton has a porous architecture that is similar
to the human trabecular bone [4]. Since its main composition
is calciumcarbonate, ahydrothermal techniquewasdeveloped
to completely convert the calcium carbonate to be coralline
hydroxyapatite (CHA) ceramics for clinical application [5–8].
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We have previously reported a coralline hydroxyapatite/
calcium carbonate (CHACC) material which shows promis-
ing clinical performance when implanted in sizes ranging
from 10–100 × 10 × 10mm3 [9, 10]. This material not only
has properties such as porosity, surface structure, and osteo-
conductivity of coralline hydroxyapatite (CHA) as previously
investigated [5–7] but also improves host tissue integration
and can be completely biodegraded during bone remodelling
[9]. Herein, we are focusing on smaller-sized CHACC, 200–
300μm particles, with the potential to be injected facilitating
administration for maxillofacial and dentistry applications.
To increase the functionality of bone biomaterials by
hopefully contributing towards remodelling and host inte-
gration, stem cells are commonly added [11]. In vitro cellular
3D structures [12] created from stem cells resembling living
tissue are known as organoids and have been developed as
models for translational medicine [13] and gene therapy [14].
We have previously shown that human bone marrow
(BM) mesenchymal stem cells (MSCs) can be cultured on
CHACC [9, 10]. Human umbilical cord matrix (UCM) is a
relatively new source of MSCs which has several advantages
over BM including an abundant supply obtained noninva-
sively; it does not induce donor site morbidity and avoids
ethical restrictions. Moreover, UCM MSCs have a higher
proliferation rate, can be expanded further without loss of
diﬀerentiation potential, and exhibit reduced immunogenic-
ity for clinical use [15]. Osteogenesis of UCM-MSCs has been
observed in both monolayer culture systems [16] and 3D cul-
ture systems, for example, on a demineralised bone [17] and
polycaprolactone tricalcium phosphate [18]. Few studies
have compared UCM MSC to BM MSC in 3D culture sys-
tems [16, 19].
Therefore, the aim of this study was to (1) conﬁrm that
MSCs could adhere to, proliferate on, and undergo osteo-
genic diﬀerentiation on 200–300μm CHACC particles to
form 3D organoids and (2) to evaluate the osteogenic poten-
tial of UCM MSCs compared to BM MSCs. MSCs were
isolated from BM and UCM and characterised by ﬂow
cytometry. CHACC was crushed into 200–300μm particles
onto which MSCs were seeded and cultured in osteogenic
diﬀerentiation medium. The resulting organoids were char-
acterised by brightﬁeld and scanning electron microscopy,
alkaline phosphatase staining, and immunocytochemistry
and PCR for key osteogenic markers.
2. Materials and Methods
2.1. Preparation of Human Bone Marrow. This study was
approved by the SouthWest Wales Research Ethics Commit-
tee (12/WA/0029) and all patients gave informed written
consent. Exclusion criteria included preexisting conditions
(e.g., connective tissue disease, diabetes, and malignancy)
or medication (e.g., steroids and cytotoxic agents). BM
aspirates were harvested from the iliac crest of two females
(aged 25 and 29 years) and two males (aged 22 and 36 years)
undergoing surgery to the pelvic ring or acetabulum using a
BM aspiration needle (Mana-Tech Ltd., Burton-on-Trent,
UK). Samples were collected in heparinised aspiration
needles, transported at room temperature, and processed
within 120min.
Mononuclear cells (MNC) were isolated from the BM
aspirate using Histopaque-1077 according to the manufac-
turer’s instructions (Sigma-Aldrich, Poole, UK). Up to
40 × 106 MNCs were seeded into 75 cm2 tissue culture ﬂasks
(CellSTAR, Greiner Bio-One, Stonehouse, UK) in 10ml
Minimum Essential Eagle Alpha Modiﬁcation media with
10% fetal calf serum (Biosera, Uckﬁeld, UK) and 1%
Antibiotic-Antimycotic (100x, Life Technologies, Paisley,
UK) and incubated for 7 days at 37°C under 5% CO2 in
air. The media were changed every 3-4 days to remove con-
taminating nonadherent haematopoietic cells, and the
adherent MSCs were cultured until 70% conﬂuent. Cells
were detached using Accutase according to the manufac-
turer’s instructions (Sigma-Aldrich) and either propagated
at a seeding density of 3 × 105 per 75 cm2 culture ﬂask or
cryopreserved in 10% dimethyl sulfoxide (DMSO) (Sigma-
Aldrich) in 90% FBS in liquid nitrogen for future use.
2.2. Preparation of Human Umbilical Cord Matrix. Human
umbilical cords and placentas were collected from full-term
births after elective caesarean section delivery of four
mothers aged 30–35 and processed within 120min. This
study was approved by the South West Wales Research
Ethics Committee and all mothers gave informed written
consent. Inclusion criteria included mothers aged 18–50
who were at least 37 weeks pregnant. Exclusion criteria
included preexisting health conditions (e.g., HIV, hepatitis
C, or immunology complications), stillborn babies, or twins.
A 3 cm section of the umbilical cord proximal to the placenta
was dissected and the vasculature was carefully removed. The
remaining matrix was ﬁnely diced using a scalpel. The diced
tissue was placed in 25 cm2 ﬂasks with 0.5ml FBS. After 24
hours, 1ml Dulbecco’s modiﬁed Eagle’s medium (DMEM,
Life Technologies, Paisley, UK) supplemented with 10%
FBS and 1% Antibiotic-Antimycotic was added. After 72
hours, an additional 3ml DMEM was added. Cultures were
subsequently fed twice weekly until 70% conﬂuent at which
point they were harvested and either propagated or cryopre-
served as above. Cryopreserved UCM MSCs and BM MSCs
were simultaneously used in the experiments for the assess-
ment on CHACC.
2.3. Characterisation by Flow Cytometry. The following
antibodies were used to phenotype the cells based on the
International Society for Cellular Therapy (ISCT) criteria
[20]: CD14-APC-eFluor780 (clone 61D3), CD34-eFluor450
(clone 4H11), CD73-FITC (clone AD2), CD90-APC (clone
eBio5E10), CD105-PE (clone SN6) (eBioscience, Hatﬁeld,
Ireland, UK), CD19-PE-Cy7 (clone J3-119), and CD45-
Krome Orange (clone J.33) (Beckman Coulter, High
Wycombe, UK). All antibodies were mouse isotype IgG1, κ.
Unstained cells were used as controls. Gating was performed
on the forward and side scatter (FSC versus SSC) proﬁle to
remove debris and doublets based on scatter. Cells (3× 105)
in 100μl FACS buﬀer (Dulbecco’s PBS, Life Technologies;
0.2% BSA and 0.05% sodium azide, Sigma-Aldrich) were
incubated on ice in the dark for 30min with predetermined
2 Stem Cells International
titrations of antibody. The cells were washed in FACS buﬀer
and resuspended in 200 μl FACS buﬀer for analysis.
The stained cells were analysed within 2 hours using a
BD FACS Aria I ﬂow cytometer with FACS Diva 6.1.3 soft-
ware (BD Bioscience, Oxford, UK). The instrument was
turned on for at least 1 hour prior to each run to allow the
lasers to warm up, and Cytometer Setup & Tracking Beads
(BD Bioscience) were used to check instrument perfor-
mance. 10,000 cell events were recorded for each antibody.
Voltages were set on unstained samples [21]. The FCS ﬁles
were analysed in Kaluza 1.2 (Beckman Coulter) and the
median ﬂuorescent intensity (MFI) was displayed on logicle
(biexponential) axes [22]. To convey information as to the
density of events, contour density plots with visualised out-
liers were chosen as the standard plot [23].
2.4. Preparation of Coralline Hydroxyapatite/Calcium
Carbonate Microscaﬀolds. CHACC (Aﬃliated Hospital,
HainanMedical College, Haikou, People’s Republic of China)
was crushed with amortar and pestle and subsequently sieved
through a 300μm followed by a 200μm sieve to capture only
200–300μm particles. The sieved CHACC were then auto-
claved for sterilisation. 10μl of complete organoid medium
(α-MEM supplemented with 10% FBS and 1% Antibiotic-
Antimycotics), and three CHACC particles were placed
into each well of a Terasaki microplate (Greiner Bio-One,
Stonehouse, UK) and incubated for 24 hours at 37°C under
5% CO2 in air.
2.5. Formation and Diﬀerentiation of Organoids. 3000 MSCs
(P3-5) per 10μl organoid medium were added to the previ-
ously prepared scaﬀold particles in the Terasaki microplates
to produce organoids. The next day, the organoids were
transferred to a 100mm petri dish (Fisher Scientiﬁc, Lough-
borough, UK) and swirled to allow the particles to come into
contact with each other, enabling a larger scaﬀold conglom-
erate to be created. The organoids were treated with either
plain organoid medium (control) or organoid medium sup-
plemented with 100nM dexamethasone, 10mM β-glycerol
phosphate, and 100μM 2-phosphate-ascorbic acid to stimu-
late osteogenic diﬀerentiation.
2.6. Characterisation by Microscopy and Live/Dead Assay.
The organoids were analysed by brightﬁeld and scanning
electron microscopy (SEM). The samples were analysed on
days 1, 7, 14, and 21 during diﬀerentiation. For SEM, the
samples were cut to 1mm diameter, ﬁxed in 4% glutaralde-
hyde (Sigma-Aldrich), and then gradually dehydrated
through an ethanol series, using sequentially higher concen-
trations of ethanol (70%, 80%, 90%, 95%, and 100%) for
10min each. Finally, samples were further dehydrated in
50% hexamethyldisilazane (Sigma-Aldrich) diluted with eth-
anol for 10min, followed by full immersion in absolute hex-
amethyldisilazane, and left to evaporate overnight in a fume
cupboard. Control scaﬀold particles (no cells) were also incu-
bated for 7 days in organoid medium, at 37°C under 5% CO2
in air, before being ﬁxed and dehydrated. SEM was carried
out using a Hitachi S-4800 II SEM with an accelerating volt-
age of 1 kV at 110x and 5000x. Samples were mounted onto
SEM stubs using a double-coated carbon conductive tape
(Acros Organics, supplied by Fisher Scientiﬁc).
Cell viability was also assessed after 14 and 21 days
using Live/Dead assay kit (Life Technologies, Paisley, UK),
in which cells were stained with calcein acetoxymethyl
(0.1μg/ml) and propidium iodide (1μg/ml) and viewed by
ﬂuorescence microscopy.
2.7. Assessing Diﬀerentiation by Immunocytochemistry. At 21
days diﬀerentiation, organoids were washed in PBS and ori-
entated within a large droplet of Bright Cryo-M-Bed embed-
ding compound which was snap frozen on dry ice. 10μm
sections were then cut using a Leica CM1900 and melted
onto slides for staining. Slides were ﬁxed in 10% neutral buﬀ-
ered formalin (Sigma-Aldrich), permeabilised in PBS : 0.1%
Triton X-100 (Sigma-Aldrich), and incubated in PBS : 0.5%
bovine serum albumin (BSA) (Sigma-Aldrich) for 30min to
block nonspeciﬁc binding. The organoids were stained with
preoptimised concentrations of monoclonal mouse primary
antibodies targeting Runx2 (3μg/ml) (R&D Systems,
Abingdon, UK), osteocalcin (10μg/ml), or polyclonal rab-
bit primary antibody targeting type I collagen (10μg/ml)
(Abcam, Cambridge, UK) overnight in a humidiﬁed environ-
ment at +4°C. Unbound primary antibody was removed by
washing in PBS and the slides were incubated for 1 hour in
the dark at room temperature with a secondary NL557-
conjugated anti-mouse or NL493-conjugated anti-rabbit
antibody (1 : 200) (R&D Systems). Slides were washed in
PBS and stained with 0.1% 4′,6-diamidino-2-phenylindole
(DAPI, Life Technologies) for 1min at room temperature.
Each sample was washed in PBS and imaged using a confocal
microscope (Zeiss LSM710, Oberkochen, Germany). Nega-
tive (no primary antibody) and blank (scaﬀold without cells)
controls were included.
2.8. Alkaline Phosphatase Staining. The slides were ﬁxed in
ice cold 70% ethanol (Fisher Scientiﬁc) for 10min after
sectioning and washed in PBS, before being immersed in
ALP substrate kit (Vector Laboratories, Peterborough,
UK) according to the manufacturer’s instructions. Slides
were stained in 0.1% DAPI (Life Technologies) for 1min
at room temperature to stain nuclei and imaged using a
confocal microscope.
2.9. Real-Time PCR Analysis. Key markers of osteogenesis
(Runx2, ALP, and type I collagen) were assessed using real-
time PCR. 21 days post diﬀerentiation, RNA was isolated
from the cells using the MasterPure kit (Cambio, Cambridge,
UK) according to the manufacturer’s instructions. In brief,
samples were lysed in 300μl of tissue and cell lysis solution
at 65°C for 30 min. Protein was precipitated out of solution
using 150μl of protein precipitation reagent. After centrifu-
gation, the supernatant was collected and incubated for 1
hour at 37 °C with deoxyribonuclease to remove DNA. This
process was then repeated. RNA was collected by precipita-
tion using 2-propanol and centrifugation. 1μg of RNA was
reverse transcribed into cDNA using RETROscript® Kit (Life
Technologies) in a reaction volume of 20μl. Real-time PCR
reactions were run at 50°C for 2min and 95°C for 2min, as
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an initial denaturation step, followed by 40 cycles at 95°C for
15 secs to denature and 60°C for 30 secs to anneal using Sso-
Fast EvaGreen Supermix and the 2005 MyiQ real-time PCR
detection system (Bio-Rad Laboratories, Hemel Hempstead,
UK). Ampliﬁcation of each gene included 10μl of SsoFast
EvaGreen®, 0.6μl forward primers, 0.6μl reverse primers,
6.8μl of nuclease free water, and 2μl of diluted cDNA
(1 : 10 with nuclease-free water). This was followed by a melt
curve analysis. The cycle threshold (CT) of ampliﬁcation for
each gene of interest (Table 1) was normalised against the
housekeeping gene GAPDH in all samples, and relative gene
expression level was determined by the 2^(GAPDH CT-Test
CT) method.
2.10. Statistical Analysis. All experiments were repeated at
least once until consistent results were obtained. Nonpara-
metric tests were used to analyse statistical data (Statistica
Version 6, StatSoft Ltd., UK). All data are expressed as
mean± standard error.
3. Results
3.1. Characterisation by Flow Cytometry.UCM and BMMSC
demonstrated the traditional MSC phenotype [20] showing
positive expression for CD73, CD90, and CD105 and nega-
tive expression for the haematopoietic markers CD14,
CD19, CD34, and CD45 (Figure 1).
3.2. Morphology Characterised by Bright Field and Scanning
Electron Microscopy. Bright ﬁeld (Figure 2) and SEM images
(Figure 3) were taken on days 1, 7, 14, and 21 of the diﬀeren-
tiation process and compared to a control image taken at day
21 with no addition of osteogenic supplement. Bright ﬁeld
images (Figure 2) showed large gaps in between particles
devoid of UCM MSCs (Figure 2(A4), white arrow) until
day 21. In contrast, BM MSCs (Figure 2(B)) were observed
to proliferate and rapidly occupy the spaces between particles
as early as day 7 and did not change in appearance after this
time point. SEM images (Figure 3) showed over time the sur-
face of the organoids to become smoother due increasing cell
density and deposition of extracellular matrix, which bound
the CHACC particles together forming a larger conglomer-
ate. Smoother surfaces were exhibited using BM MSCs
(Figure 3(B3)) at day 14, whereas UCMMSCs (Figure 3(A4))
did not cover the entire surface until day 21. The addition of
osteogenic supplement was not observed to have any signiﬁ-
cant impact onorganoidmorphology in relation to the control
images at 21 days.
Cell viability was also assessed after 14 and 21 days using
Calcein acetoxymethyl (0.1μg/ml) and propidium iodide
(1μg/ml) and viewed by ﬂuorescence microscopy. Dead cells
were barely observed on CHACC using UCM or BM MSCs,
which demonstrated that the cell viability was not aﬀected
by CHACC microparticles.
3.3. Osteogenesis Characterised by Immunocytochemistry and
Alkaline Phosphatase Staining. UCM and BM MSCs were
observed throughout the organoid by 21 days of diﬀeren-
tiation. Excluding UCM MSCs grown in control α-MEM
that did not label for ALP (Figure 4(a), A1), osteogenically
induced and noninduced organoids were positive for ALP
(Figure 4(a), A2–A4), Runx2 (Figure 4(b), B1–B4), type I col-
lagen, and osteocalcin (Figure 4(c), C1–C4). ALP was
active within the MSC’s cytoplasm. Runx2 was largely
found within the nucleus of MSCs and appeared purple
due to blending with the nuclear stain DAPI. Type I col-
lagen and osteocalcin were found within the extracellular
matrix on the surface of the organoid.
ALP (Figure 4(a), A5), Runx2 (Figure 4(b), B5), and type
I collagen (Figure 4(c), C5) were also assessed by real-time
PCR. Osteogenically induced BM MSCs were shown to
have signiﬁcantly more ALP (Figure 4(a), A5) and Runx2
(Figure 4(b), B5) mRNA than osteogenically induced UCM
MSCs, relative to the housekeeping gene, GAPDH. However,
control BMMSCs were also shown to have signiﬁcantly more
Runx2 mRNA compared to UCM MSC. Nonosteogenically
induced UCM MSCs showed high type I collagen mRNA
and protein expression but low ALP and Runx2.
4. Discussion
Novel biomaterials for bone regeneration are desired as they
do not have inherent disadvantages of autografts (blood loss,
infection and morbidity risks, and limited supply). However,
they need to match the gold standard of autografts in bone
replacement surgery. CHACC has been shown to have excel-
lent properties to function as a bone graft, but it lacks the key
component required for autografts: living cells with osteo-
genic capacity.
In this study, UCM and BM MSCs were incorporated
with CHACC microparticles to form organoids and their
in vitro osteogenic potential was assessed and compared.
Human UCM MSCs have been proven to diﬀerentiate down
the osteogenic lineage and share common surface markers to
BM MSCs [15]. CHACC is already used as a bone graft.
Therefore, it was expected to provide a 3D structure for
UCM and BM MSC attachment, proliferation, and
Table 1: Primer sequences used in real-time PCR.
Gene Forward primer (5′-3′) Reverse primer (5′-3′)
Glyceraldehyde-3-phosphate dehydrogenase TCA TTG ACC TCA ACT ACA TGG T TCT CGC TCC TGG AAG ATG GTG
RUNX2 CCT AGG CGC ATT TCA GGT GCT T CTG AGG TGA CTG GCG GGG TGT
Type I collagen ATG TTC AGC TTT GTG GAC CTC CGG CGC AGG TGA TTG GTG GGA TGT CT
Alkaline phosphatase GAC CCT TGA CCC CCA CAA T GCT CGT ACT GCA TGT CCC CT
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diﬀerentiation. Organoids can result in increased cell num-
bers compared to the cell suspension method [24], and the
hydroxyapatite layer on CHACC should accelerate the diﬀer-
entiation of cells and consequently mineralisation [24–26].
Although both BM and UCM MSCs were able to attach
to CHACC microparticles, form organoids, proliferate, and
diﬀerentiate down the osteogenic lineage, as expected, the
BM MSCs showed higher levels of osteogenic diﬀerentiation
than UCM MSCs. BM MSCs showed a dramatic increase in
cell proliferation indicating that they entered into the ﬁrst
stage of osteogenic diﬀerentiation [27] before UCM MSCs.
Increased osteogenic diﬀerentiation in BMMSCs was further
evidenced by increased expression of runx2 and ALP and the
labelling of osteocalcin in immunocytochemistry [25]. Other
researchers have also found BMMSCs to have superior oste-
ogenic potential compared to UCM MSCs [28]. Similar to
our study, Schneider et al. found BM MSCs to express more
ALP but less type I collagen than UCM MSCs [29]. Zhang
et al. compared MSCs on 3D scaﬀolds derived from diﬀerent
sources and found BM MSCs to form more bone than
UCM MSC [18]. Reduced osteogenic potential of UCM
MSCs maybe explained by the anatomical origins that they
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Figure 1: Human UCM and BM MSCs single stained with antibodies against surface markers. MSCs were CD14-CD19-CD34-CD45-
CD73+CD90+ and CD105+, correlating with an MSC phenotype deﬁned by ISCT. Grey: unstained; black: stained.
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were derived from. Panepucci et al. found higher levels of
genes related to osteogenesis in BM MSCs compared to
umbilical cord vein MSCs [30]. Umbilical cord vein MSCs
expressed genes more related to matrix remodelling via
metalloproteinases and angiogenesis. Consequently, UCM
MSCs could be less committed to osteogenesis but instead
committed to angiogenesis.
Interestingly, Zhang et al. also showed that UCM MSCs
could diﬀerentiate down the osteogenic lineage better than
BM MSCs if they were cultured in monolayer [18]. Based on
this study, future work should investigate diﬀerentiating
UCMMSCs in monolayer ﬁrst and then seed these cells onto
3D scaﬀolds. Although ectopic bone formation using UCM
MSCs has been proven to be inferior compared to BM MSCs
in vivo, the angiogenic nature of UCMs has been utilised to
improve bone regeneration. Todeschi et al. showed that
UCM MSCs implanted orthotopically caused a similar
amount of new bones to form compared to BM MSCs by
recruiting host osteogenic cells [31]. Chen et al. also utilised
the angiogenic nature of umbilical cord mesenchymal stem
cells by coculturing them with human umbilical cord vein
endothelial cells. They found that a similar amount of new
bone formation could be achieved in vivo compared to cocul-
turing human umbilical cord vein endothelial cells with BM
MSCs [32].
There are a number of limitations to this study; immuno-
cytochemistry and real-time PCR only assess a narrow spec-
trum of markers, meaning MSCs could be diﬀerentiating
down a lineage not being speciﬁcally looked at. Furthermore,
quantitative PCR only gives a snap shot of RNA expression at
the day it is extracted and has a very short half-life of approx-
imately 9 hours [33] meaning expression levels could be
missed. Cell attachment and growth was limited to arbitrary
qualitative assessment via bright ﬁeld and SEM images.
Future work is expected to overcome the inferior osteo-
genic capacity of UCM MSCs, such as to initiate the osteo-
genic diﬀerentiation at 2D culture stage, and the osteogenic
gene and protein expression will be assessed at more time
points to show the full spectrum of diﬀerentiation over the
three-week period or longer to assess the full potential of
UCM MSCs. Also, to utilise the angiogenic nature of UCM,
MSCs with CHACC should be explored as well.
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Figure 2: Bright ﬁeld images of organoids with UCM (A) and BM
(B) MSCs during the process of osteogenesis. Images were taken
on days 1 (A1, B1), 7 (A2, B2), 14 (A3, B3), and 21 (A4, B4) of the
diﬀerentiation process and compared to a control (α-MEM) image
at day 21 (A5, B5). BM MSCs were observed to proliferate into the
voids created by the numerous coral particles by day 7 and UCM
MSCs by day 7 (white arrows). SP: scaﬀold particle. Scale bars:
250μm.
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Figure 3: SEM images of organoids with UCM (A) and BM (B)
MSCs during the process of osteogenesis. Images were taken on
days 1 (A1, B1), 7 (A2, B2), 14 (A3, B3), and 21 (A4, B4) of the
diﬀerentiation process and compared to a control (α-MEM) image
at day 21 (A5, B5). Over time, the voids within the organoid were
ﬁlled with MSCs and associated extracellular matrix which formed
a smoother surface that covered CHACC surfaces. Signiﬁcant
coverage was exhibited using BM MSCs at day 14 (B3), whereas
UCM MSCs did not cover surfaces until day 21 (A4). Scale bars:
500 μm.
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5. Conclusion
This study has shown that 200–300μm CHACC granules
can be a suitable carrier for human MSC proliferation
and diﬀerentiation in vitro, for the purpose of injectable
delivery opening up the use of CHACC for new applica-
tions within maxillofacial surgery and dentistry. In addi-
tion, UCM MSCs show inferior osteogenic capacity when
cultured as CHACC organoids compared to BM MSCs.
Therefore, further research is required to optimise the
osteogenicity of UCM MSCs to release their full potential as
a readily available, accessible, and abundant tissue source
for bone tissue engineering.
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Figure 4: On day 21, control and osteogenically induced organoids were cryosectioned (10 μm) and stained for alkaline phosphatase (ALP)
(a), Runx2 (b), collagen type I, and osteocalcin (c). Real-time PCRwas used to assess mRNA levels of ALP (A5), Runx2 (B5), and collagen type
I (C5) in UCM and BM MSCs lysed directly from the control and osteogenically induced scaﬀolds at 21 days. MSCs derived from UCM
expressed good collagen I mRNA and protein production but poor ALP and Runx2 in relation to MSCs derived from BM. n = 4 (∗p < 0 05).
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